Nexera Pharma announced that it has entered into a licensing agreement with Taiwan’s major pharmaceutical company Simcere BioPharma for the exclusive launch of its insomnia treatment Quviviq in 8 countries, including Southeast Asia and Oceania.
Nexera Pharma Japan, the Japanese subsidiary of Nexera Pharma, entered into a licensing agreement with Taiwan’s major pharmaceutical company Simcere BioPharma covering Quviviq, an insomnia treatment, in 8 countries including Southeast Asia and Oceania. Under the agreement, Simcere will hold the exclusive rights to apply for, obtain and commercialize approval in the covered territories. Simcere will lead distribution and sales, while Nexera Pharma will handle product supply and regulatory support.
As consideration under the agreement, Nexera Pharma is expected to receive upfront payments, royalties and product supply revenue, giving it the right to receive a portion of future revenue. The covered territories include Southeast Asia and Oceania, including Thailand, Indonesia and Australia.